Cargando…

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2

Cancer biomarkers that can define disease status and provide a prognostic insight are essential for the effective management of patients with breast cancer (BC). The prevalence, clinicopathological and prognostic significance of PRPF38B expression in a consecutive series of 1650 patients with primar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel-Fatah, Tarek M.A, Rees, Robert C, Pockley, A. Graham, Moseley, Paul, Ball, Graham R, Chan, Stephen Y.T, Ellis, Ian O, Miles, Amanda K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762507/ https://www.ncbi.nlm.nih.gov/pubmed/29348822 http://dx.doi.org/10.18632/oncotarget.22496

Ejemplares similares

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

The role of splicing factor PRPF8 in breast cancer
por: Cao, Difei, et al.
Publicado: (2022)

Regulation of constitutive and alternative mRNA splicing across the human transcriptome by PRPF8 is determined by 5′ splice site strength
por: Wickramasinghe, Vihandha O., et al.
Publicado: (2015)

PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA
por: Yano, Kimiyoshi, et al.
Publicado: (2021)

Disrupted alternative splicing for genes implicated in splicing and ciliogenesis causes PRPF31 retinitis pigmentosa
por: Buskin, Adriana, et al.
Publicado: (2018)

Temporal and Tissue Specific Regulation of RP-Associated Splicing Factor Genes PRPF3, PRPF31 and PRPC8—Implications in the Pathogenesis of RP
por: Cao, Huibi, et al.
Publicado: (2011)

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer
por: Abdel-Fatah, T M A, et al.
Publicado: (2014)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

Prpf31 is essential for the survival and differentiation of retinal progenitor cells by modulating alternative splicing
por: Li, Jingzhen, et al.
Publicado: (2021)

Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab
por: Sorscher, Steven
Publicado: (2013)

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
por: Nahta, Rita
Publicado: (2012)

Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
por: Mann, K, et al.
Publicado: (2016)

Mutant Prpf31 causes pre-mRNA splicing defects and rod photoreceptor cell degeneration in a zebrafish model for Retinitis pigmentosa
por: Yin, Jun, et al.
Publicado: (2011)

Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts()
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2014)

Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma
por: Song, Huijuan, et al.
Publicado: (2020)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
por: Li, Xin, et al.
Publicado: (2018)

PRPF overexpression induces drug resistance through actin cytoskeleton rearrangement and epithelial-mesenchymal transition
por: Islam, Salman Ul, et al.
Publicado: (2017)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
por: Xing, Fei, et al.
Publicado: (2023)

Intermediate Uveitis in Retinitis Pigmentosa Associated with a Novel Homozygous Splice Site Mutation in PRPF8
por: Badawi, Abdulrahman H., et al.
Publicado: (2022)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Alterations in mRNA profiles of trastuzumab-resistant Her-2-positive breast cancer
por: Zhao, Bin, et al.
Publicado: (2018)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids
por: Rodríguez, Cristina E., et al.
Publicado: (2015)

Disease mechanism for retinitis pigmentosa (RP11) caused by missense mutations in the splicing factor gene PRPF31
por: Wilkie, Susan E., et al.
Publicado: (2008)

Increased versatility despite reduced molecular complexity: evolution, structure and function of metazoan splicing factor PRPF39
por: De Bortoli, Francesca, et al.
Publicado: (2019)

Human PRPF40B regulates hundreds of alternative splicing targets and represses a hypoxia expression signature
por: Lorenzini, Paolo Alberto, et al.
Publicado: (2019)

PRPF8 increases the aggressiveness of hepatocellular carcinoma by regulating FAK/AKT pathway via fibronectin 1 splicing
por: López-Cánovas, Juan L., et al.
Publicado: (2023)

Variants in the PRPF8 Gene are Associated with Glaucoma
por: Micheal, Shazia, et al.
Publicado: (2017)

Prognostic potential of PRPF3 in hepatocellular carcinoma
por: Liu, Yinlan, et al.
Publicado: (2020)

mRNA Profiling Reveals Determinants of Trastuzumab Efficiency in HER2-Positive Breast Cancer
por: von der Heyde, Silvia, et al.
Publicado: (2015)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
por: Harder, J, et al.
Publicado: (2012)

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
por: Arteaga, Carlos L
Publicado: (2003)

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression
por: Aboudaram, Amélie, et al.
Publicado: (2021)

PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
por: Yokoyama, Daiju, et al.
Publicado: (2021)

ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_iq8jitjjg304a6o4foinho1pgp